Relevant bibliographies by topics / Squamous cell lung cancer, prognosis, NGS, RICTOR

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Squamous cell lung cancer, prognosis, NGS, RICTOR'

Author: Grafiati
Published: 11 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Squamous cell lung cancer, prognosis, NGS, RICTOR.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Squamous cell lung cancer, prognosis, NGS, RICTOR"

1

Cheng, Haiying, Ni Fan, Ethan Sokol, et al. "RICTOR amplification as a novel therapeutic target for lung cancer brain metastases." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3597. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3597.

Full text
Abstract:
3597 Background: Approximately 20% to 50% of patients with advanced lung cancer develop brain metastases, which are associated with debilitating neurologic impairment and a dismal prognosis. There have been very limited studies investigating the genomics of brain metastases in lung cancer. Methods: We comprehensively investigated the frequency of PI3K/AKT/RICTOR/mTOR pathway aberrations in primary and metastatic sites using an extensive database of 11845 cases of lung adenocarcinoma by NGS (FoundationOne). The potential roles of RICTOR amplification in the development of brain metastases were
APA, Harvard, Vancouver, ISO, and other styles
2

Goffinet, Samantha, Veronique Hofman, Christophe Bontoux, et al. "EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): 8539. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.8539.

Full text
Abstract:
8539 Background: EGFR status assessment is mandatory in early stage (IB-IIIA) non-squamous non-small cell lung carcinoma (NS-NSCLC), but whether NGS methods should be used as reflex testing for this evaluation in daily practice is controversial. However, co-occuring mutations, notably TP53 mutations, may have an impact on tumor behavior and prognosis, and so, on future adjuvant therapeutic strategies. Methods: EGFR mutations were assessed prospectively using NGS (Oncomine Precision Assay genes panel) in 720 NS-NSCLC surgically resected between January 2021 and September 2022 in a single instit
APA, Harvard, Vancouver, ISO, and other styles
3

Laktionov, K. K., K. A. Sarantseva, L. A. Nelyubina, S. V. Gamayunov, E. A. Kolesnikova, and M. G. Gordiev. "KRAS-mutated non-small cell lung cancer: new therapy strategies." Siberian journal of oncology 23, no. 2 (2024): 72–81. http://dx.doi.org/10.21294/1814-4861-2024-23-2-72-81.

Full text
Abstract:
Lung cancer remains one of the most dangerous and most common cancers, requiring constant improvement of diagnostic and treatment methods. The genetic heterogeneity of lung cancer forces us to search for new therapeutic targets in an attempt to achieve greater effectiveness for certain groups of patients. The purpose of the study was to update current knowledge about lung adenocarcinoma with a mutation in the KRAS gene, to consider new opportunities for personalized treatment of KRAS-mutated NSCLC and to form an image of a Russian patient who is potentially indicated for targeted therapy. Mate
APA, Harvard, Vancouver, ISO, and other styles
4

Kato, Terufumi, Shingo Matsumoto, Shigeki Umemura, et al. "Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer: A result of nationwide genome screening in Japan (LC-SCRUM-Japan)." Journal of Clinical Oncology 37, no. 15_suppl (2019): 9060. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9060.

Full text
Abstract:
9060 Background: Various gene alterations occur during the development of squamous cell lung cancer (SqLC), but specific gene alterations for SqLC and their clinical significance remain unknown. Methods: In a nationwide genome screening project (LC-SCRUM-Japan), we have prospectively analyzed lung cancer patients for genetic alterations using a next-generation sequencing (NGS) system, Oncomine Comprehensive Assay, and have established a large-scale clinico-genomic database. Results: Since February 2013 to December 2018, a total of 6692 lung cancer patients (686 SqLCs, 5360 non-squamous non-sma
APA, Harvard, Vancouver, ISO, and other styles
5

Wu, Fang, Chunhong Hu, Sujuan Zhang, et al. "Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib." Journal of Clinical Oncology 41, no. 16_suppl (2023): e18074-e18074. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18074.

Full text
Abstract:
e18074 Background: Epidermal growth factor receptor (EGFR) mutation is most commonly oncogenic driver in lung adenocarcinoma with 50% incidence in Asians.Osimertinib is the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which has been widely used in metastatic EGFR-mutant non-small cell lung cancer (NSCLC) and has significantly improved outcomes. At present, the treatment of HNSCC mainly relies on surgery or chemoradiotherapy. EGFR is overexpressed in more than 90% of head and neck squamous cell carcinoma (HNSCC). Targeted therapy for HNSCC is mainly mo
APA, Harvard, Vancouver, ISO, and other styles
6

Ohashi, Kadoaki, Shingo Matsumoto, Kiyotaka Yoh, et al. "Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e20659-e20659. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20659.

Full text
Abstract:
e20659 Background: A nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) was established in 2013. The objective of this project is to contribute to the development of precision medicine through the genomic biomarker screening, leading to improvement of patient prognoses. Methods: Advanced non-squamous non-small cell lung cancer (non-sq NSCLC) without EGFR mutations were eligible for inclusion. The tumors were analyzed for ALK/ROS1/RET fusions using RT-PCR and FISH. Since March 2015, the samples were further subjected to a next-generation sequencing (NGS) system, Oncomine
APA, Harvard, Vancouver, ISO, and other styles
7

Charkiewicz, Radoslaw, Anetta Sulewska, Alicja Charkiewicz, et al. "miRNA-Seq Tissue Diagnostic Signature: A Novel Model for NSCLC Subtyping." International Journal of Molecular Sciences 24, no. 17 (2023): 13318. http://dx.doi.org/10.3390/ijms241713318.

Full text
Abstract:
Non-small cell lung cancer (NSCLC) encompasses distinct histopathological subtypes, namely adenocarcinoma (AC) and squamous cell lung carcinoma (SCC), which require precise differentiation for effective treatment strategies. In this study, we present a novel molecular diagnostic model that integrates tissue-specific expression profiles of microRNAs (miRNAs) obtained through next-generation sequencing (NGS) to discriminate between AC and SCC subtypes of NSCLC. This approach offers a more comprehensive and precise molecular characterization compared to conventional methods such as histopathology
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Hongbiao, Yingcheng Lin, Jun Liu, Yuyin Cai, Xiaofang Qi, and Lujia Huang. "Abstract 5742: The landscape of genetic alteration in Chinese lung adenosquamous carcinoma patients." Cancer Research 82, no. 12_Supplement (2022): 5742. http://dx.doi.org/10.1158/1538-7445.am2022-5742.

Full text
Abstract:
Abstract Background: Lung adenosquamous carcinoma (LASC) is a mixed histologic component tumor type that contains both squamous cell carcinoma and adenocarcinoma, with each component accounting for at least 10% of tumors. The incidence of LASC is very low, only comprising 0.4-4% of all lung cancers. LASC yields a more aggressive clinical course, and its prognosis is generally worse than that of adenocarcinoma and squamous cell carcinoma of the lung. Due to the rarity of LASC, currently, there is no standard treatment. Also, to date, limited genomic data have been performed. In this study, we a
APA, Harvard, Vancouver, ISO, and other styles
9

Pai, Tanmayi, Marte Wasserman, Jason Lewis, et al. "Abstract PO2-20-08: Metastatic Lung Cancer Masquerading as Metaplastic Breast Cancer." Cancer Research 84, no. 9_Supplement (2024): PO2–20–08—PO2–20–08. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-20-08.

Full text
Abstract:
Abstract Background Metaplastic breast carcinoma (MBC) is an unusual malignancy that presents a diagnostic challenge due to the presence of varying cytomorphologies that can be seen in benign and malignant tumors. We posit that metastatic disease to the breast, itself an uncommon entity, should be considered in the differential diagnosis of MBC. We report a unique case of metastatic non-small cell lung cancer (NSCLC) with an actionable driver mutation that presented as a symptomatic breast mass and was initially considered to represent MBC. Report A 74-year-old woman with a 22-pack-year smokin
APA, Harvard, Vancouver, ISO, and other styles
10

John, Felix, Lea Ruge, Heather Scharpenseel, et al. "Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring KRAS G12V mutations." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8618. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8618.

Full text
Abstract:
8618 Background: KRAS G12V is one of the most common drivers of non-small cell lung cancer (NSCLC), accounting for around 3 percent of cases. Recently, there have been promising approaches in early clinical research to therapeutically target this mutation. However, this subset of patients is poorly characterized both molecularly and clinically, and data on therapy-dependent outcome are lacking. We performed this real world analysis to gain insight into the genomic and clinical characteristics of a large cohort of NSCLC patients with KRAS G12V mutations. Methods: Molecular data of 662 UICC stag
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Squamous cell lung cancer, prognosis, NGS, RICTOR"

1

Pilotto, Sara. "Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC)." Doctoral thesis, 2019. http://hdl.handle.net/11562/994946.

Full text
Abstract:
Differently from lung adenocarcinoma, effective targeted therapies for lung squamous-cell cancer (SQLC) are still missing, although a series of molecular pathways are constantly altered. In this regard, the prognostic and/or predictive impact of potential drivers needs to be elucidated, in order to create a global portrait of SQLC patients. Nowadays, one of the main emerging research strategies in cancer is centered on the study of the genome of exceptional responder and prognostic outlier patients. Adopting this idea, we retros
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Squamous cell lung cancer, prognosis, NGS, RICTOR' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography